PTAB invalidates Teva’s Copaxone patents

The Patent Trial and Appeal Board (PTAB) has invalidated claims in two Teva-owned patents covering Copaxone (glatiramer acetate injection), prompting the Israel-based company to announce its intention to appeal against the ruling.

Teva, which made the announcement yesterday, August 24, will appeal to the US Court of Appeals for the Federal Circuit.

Mylan had opposed the patents covering the multiple sclerosis treatment in an inter partes review petition at the PTAB.

The patents, US numbers 8,232,250 and 8,399,413, are owned by Yeda  Research & Development and licensed to Teva.

They expire in 2030 and cover administering the drug in a 40-milligram dosage three times a week.

Erez Vigodman, CEO of Teva, said: “We remain confident in the strength of our intellectual property surrounding Copaxone 40mg.”

He added: “We are prepared to defend the full suite of our IP through the PTAB and the US courts regardless of the time required.”